Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Routine breast cancer screening can bring better outcomes for patients

2.

Blood tests can predict the risk of relapse after a bone marrow transplant in patients with acute myeloid leukemia.

3.

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

4.

Testosterone recovery linked to overall survival in high-risk prostate cancer

5.

Skinny melanoma incidence is associated with vitamin D deficiency.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot